The Antitrust Authority has summoned the companies to review the compromise that let them hold the Leviathan gas reserve.
Shimon Peres: You can't feed the hungry with declarations. Likud: The declarations are the left's mud-slinging.
Israel's unemployment rate fell to 5.6% in November, while the rate of participation in the workforce rose.
Families renting a larger home and renting out their smaller home should get a tax break.
Mirland CEO Roman Rozental addressed a bondholders meeting today on the coampny's Russian business.
Bloomberg reports that two Chinese ministers have said their country will assist Russia in overcoming its financial crisis.
"Global Property Guide" reports that Israeli home prices rose by 6.43% in the year ending September 30 2014.
Israel Corp's Chinese car joint venture is undergoing a managerial shakeup, "Chinese Business News" reports.
An underpass and light rail station will be built at one of the city's busiest intersections.
Transport & infrastructure
The QNASL nasal spray, approved for adults in 2012, treats nasal symptoms for allergic rhinitis, including hay fever, in children.
Israel Chemicals is selling the footwear materials supplier to a German investor.
Mergers & acquisitions
Chairman & CEO, Rubicon Business Group Ltd.
Energy stocks led the TASE lower today, but it was a better day for companies doing real estate business in Russia.
Strategic enemies are weakened, while any Israeli oil could come on stream right on time.
FXCM Israel: Volumes and volatility will be low during the Christmas week.
Governor of the Bank of Israel Karnit Flug says Israel's public spending lags the OECD partly because of low taxes.
Such a measure by a transition government requires approval from the Attorney General.
The first tender in the target price track in Rosh Ha'ayin is scheduled to get underway this week.
ScotiaBank has signed an agreement to buy Israel Discount Bank's Uruguay unit for $65 million.
As parent company Jerusalem Economy tumbles, Fishman Group sources insist the financial repercussions will not be significant.
The agreement gives Medivation the license to develop and commercialize Curetech's pidilizumab cancer treatment.